9d agoThe FlyBEARISH 34Analyst
Archived explainer. For the current picture see today's RARE page.
Why Is ULTRAGENYX PHARMACEU (RARE) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 11:21 PM ET · reviewed against 11 wire stories
ULTRAGENYX PHARMACEU (RARE) is drawing unusual attention today. Our newswire has captured 11 stories on RARE across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 33/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RARE stock is moving today
Ultragenyx Pharmaceutical (RARE) is moving lower today amid a wave of downgrades and a failed clinical trial. The stock opened with a modest gap up but has since fallen into a downward trend, trading at $15.40 with a session high of $16.08. The decline follows the company's announcement that its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet key endpoints. This setback has increased risk for the rare disease specialist and triggered multiple analyst downgrades.
What Happened
Ultragenyx shares are under pressure after the failed Angelman syndrome trial, which is a key therapeutic area for the company. Morgan Stanley downgraded the stock to Equal Weight from Overweight, while Barclays cut its price target to $32 from $43. Jefferies and JP Morgan also reduced their price targets, with JP Morgan setting a new target of $36. Goldman Sachs maintained a neutral stance but lowered its price target to $19. These developments have contributed to a broader sense of pessimism in the market.
The stock has fallen sharply over the past eight sessions, dropping 39.9% from $26.24 to $15.77. This comes as insiders, including the CFO and an executive vice president, have sold shares in recent months. The sentiment trend has also deteriorated, with the 30-day average at 45/100 and the last seven days at 34/100.
What The Data Shows
Intraday trading has shown a volatile session, with the stock opening at $15.10 and reaching a high of $16.08 before retreating. Volume has surged to 9.9 million shares, nearly 4.5 times the 3-month average. The 52-week tape has recorded six fresh 52-week lows and six highs on September 4, reflecting the stock's extreme price swings. Unusual options activity has also been noted, with $716K in call premiums traded over the last 36 hours.
What To Watch
Ultragenyx has no scheduled earnings date in the immediate future. Investors will need to monitor coverage breadth and any further analyst actions as the stock remains under pressure from both clinical setbacks and shifting analyst sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RARE by the numbers
7 sessions: -39.90%Coverage: 11 stories / 5 sourcesAI sentiment: 33/100 (bearish)Mkt cap: $2.6B52w: $13.81 to $39.89
The headlines behind the move
9d agoStocktwits NewsBEARISH 34General
Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows?
NIO, Ultragenyx Pharmaceutical and McDonald's slipped to annual lows on Thursday amid company-related pressures and Wall Street pessimism around the stocks.
9d agoStocktwits NewsBEARISH 32General
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.
9d agoYahoo TopNEUTRAL 50General
Stocks to Watch Thursday Recap: Snowflake, Broadcom, HPE, Ultragenyx
9d agoSeeking AlphaBEARISH 28Earnings
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist
Ultragenyx shares plunged after its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet key endpoints. Click for an analysis on RARE.
9d agoThe FlyBEARISH 32Analyst
Ultragenyx downgraded at Morgan Stanley after Angelman study fails
9d agoCNBCNEUTRAL 50General
Stocks making the biggest moves midday: Tesla, Ciena, Meta, Snowflake, Ultragenyx Pharmaceutical & more
Here are some of the companies making headlines in midday trading.
9d agoThe FlyBEARISH 38Analyst
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RARE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RARE move explainers: 2026-09-04 · 2026-09-03